NASDAQ:APLS

Apellis Pharmaceuticals - APLS Stock Forecast, Price & News

$50.36

+2.84 (+5.98%)

(As of 12/8/2022 12:00 AM ET)

Add

Compare

Today's Range: $46.75
▼
$50.54
50-Day Range: $43.24
▼
$68.30
52-Week Range: $33.32
▼
$70.00

Volume: 1.34 million shs
Average Volume: 1.24 million shs
Market Capitalization: $5.57 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $73.00

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 43.3% Upside
$72.15 Price Target
Short Interest: Bearish
9.40% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.27
Upright™ Environmental Score
News Sentiment: -0.12
Based on 8 Articles This Week
Insider Trading: Selling Shares
$2.27 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.29) to ($5.17) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

263rd out of 1,022 stocks

Pharmaceutical Preparations Industry

109th out of 499 stocks

4.3

Analyst's Opinion

Consensus Rating
Apellis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $72.15, Apellis Pharmaceuticals has a forecasted upside of 43.3% from its current price of $50.36.
Amount of Analyst Coverage
Apellis Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.40% of the outstanding shares of Apellis Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Apellis Pharmaceuticals has recently increased by 6.78%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Apellis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Apellis Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Apellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Apellis Pharmaceuticals is -1.27.

1.0

News and Social Media Coverage

News Sentiment
Apellis Pharmaceuticals has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Apellis Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 9 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,265,392.00 in company stock.
Percentage Held by Insiders
Only 8.00% of the stock of Apellis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
82.75% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($6.29) to ($5.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Apellis Pharmaceuticals is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Apellis Pharmaceuticals is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Apellis Pharmaceuticals has a P/B Ratio of 24.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Stock News Headlines

December 7, 2022 | finance.yahoo.com

Apellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?

December 4, 2022 | americanbankingnews.com

Federico Grossi Sells 2,500 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

November 29, 2022 | barrons.com

Premarket Movers: Elbit Systems, CME Group Cl A, Apellis Pharmaceuticals

November 18, 2022 | benzinga.com

Looking At Apellis Pharmaceuticals's Recent Unusual Options Activity

November 18, 2022 | marketwatch.com

Apellis Shares Jump Premarket as FDA Accepts Amendment >APLS

November 18, 2022 | markets.businessinsider.com

Apellis : FDA Accepts Pegcetacoplan NDA Amendment For Geographic Atrophy; Stock Up

November 18, 2022 | finance.yahoo.com

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

November 8, 2022 | markets.businessinsider.com

5 Analysts Have This to Say About Apellis Pharmaceuticals

October 16, 2022 | seekingalpha.com

Citi lists four more value-creating events in biotech for this year

October 12, 2022 | finance.yahoo.com

Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS

October 3, 2022 | finance.yahoo.com

Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today

September 8, 2022 | markets.businessinsider.com

Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know

September 7, 2022 | seekingalpha.com

Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura

September 1, 2022 | finance.yahoo.com

Apellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two Years

August 24, 2022 | msn.com

Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study

August 24, 2022 | seekingalpha.com

Apellis stock rises as 2-year data of pegcetacoplan for eye disorder shows promise

August 24, 2022 | finance.yahoo.com

Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)

August 8, 2022 | seekingalpha.com

Apellis Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

August 8, 2022 | seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call Transcript

August 8, 2022 | finance.yahoo.com

Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results

July 19, 2022 | msn.com

Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review

July 19, 2022 | finance.yahoo.com

Apellis Pharmaceuticals Stock Jumps After FDA Accepts Drug for Review

July 13, 2022 | finance.yahoo.com

Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade

July 8, 2022 | finance.yahoo.com

Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

July 2, 2022 | morningstar.com

Apellis Pharmaceuticals Inc - Stock Chart

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings: 11/07/2022
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APLS
CUSIP: N/A
CIK: 1492422
Web: www.apellis.com
Phone: (617) 977-5700
Fax: N/A
Employees: 476
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $72.15
High Stock Price Forecast: $123.00
Low Stock Price Forecast: $40.00
Forecasted Upside/Downside: +45.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-746,350,000.00
Net Margins: -560.92%
Pretax Margin: -558.72%
Return on Equity: -194.70%
Return on Assets: -64.99%

Debt

Debt-to-Equity Ratio: 0.30
Current Ratio: 7.21
Quick Ratio: 6.69

Sales & Book Value

Annual Sales: $66.56 million
Price / Sales: 83.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.04 per share
Price / Book: 24.69

Miscellaneous

Outstanding Shares: 110,576,000
Free Float: 101,730,000
Market Cap: $5.57 billion
Optionable: Not Optionable
Beta: 1.17

Key Executives

Dr. Cedric Francois M.D. (Age 50)
Ph.D., Co-Founder, Pres, CEO & Director
Comp: $969.54k

Dr. Pascal Deschatelets Ph.D. (Age 52)
Co-Founder & Chief Scientific Officer
Comp: $609.85k

Dr. Federico Grossi M.D. (Age 48)
Ph.D., Co-Founder & Chief Medical Officer
Comp: $578.01k

Mr. Alec Machiels J.D. (Age 49)
MBA, Co-Founder & Director
Comp: $72.5k

Mr. Timothy E. Sullivan (Age 51)
CFO & Treasurer
Comp: $630.17k

Mr. Adam J. Townsend (Age 45)
Chief Commercial Officer
Comp: $602.69k

Ms. Nur Nicholson
Chief Technical Operations Officer

Mr. James G. Chopas CPA (Age 56)
VP, Corp. Controller & Chief Accounting Officer

Ms. Meredith Kaya
Sr. VP, Investor Relations & Strategic Fin.

Mr. David O. Watson Esq. (Age 49)
J.D., Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.
What is Apellis Pharmaceuticals' stock price forecast for 2023?: 13 brokers have issued 12-month price targets for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $40.00 to $123.00. On average, they expect the company's share price to reach $72.15 in the next year. This suggests a possible upside of 43.3% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.
How have APLS shares performed in 2022?: Apellis Pharmaceuticals' stock was trading at $47.28 at the beginning of 2022. Since then, APLS stock has increased by 6.5% and is now trading at $50.36.
View the best growth stocks for 2022 here.
When is Apellis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our APLS earnings forecast.
How were Apellis Pharmaceuticals' earnings last quarter?: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its earnings results on Monday, November, 7th. The company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by $0.27. The firm earned $22.06 million during the quarter, compared to analysts' expectations of $19.82 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 194.70% and a negative net margin of 560.92%.
What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?: 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).
When did Apellis Pharmaceuticals IPO?: (APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.
What is Apellis Pharmaceuticals' stock symbol?: Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."
Who are Apellis Pharmaceuticals' major shareholders?: Apellis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.17%), BlackRock Inc. (6.41%), Price T Rowe Associates Inc. MD (3.03%), State Street Corp (2.67%), Jennison Associates LLC (2.31%) and Cormorant Asset Management LP (1.34%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Victoria L Brown and Victoria L Brown.
View institutional ownership trends.
How do I buy shares of Apellis Pharmaceuticals?: Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Apellis Pharmaceuticals' stock price today?: One share of APLS stock can currently be purchased for approximately $50.36.
How much money does Apellis Pharmaceuticals make?: Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $5.57 billion and generates $66.56 million in revenue each year. The company earns $-746,350,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis.
How many employees does Apellis Pharmaceuticals have?: The company employs 476 workers across the globe.
How can I contact Apellis Pharmaceuticals?: Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Apellis Pharmaceuticals - APLS Stock Forecast, Price & News

Apellis Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™